<DOC>
	<DOCNO>NCT01018810</DOCNO>
	<brief_summary>In study , evaluate clinical activity , safety , tolerability , pharmacokinetics , pharmacodynamics , immunogenicity 5 LY2525623 dose group compare placebo adult plaque psoriasis .</brief_summary>
	<brief_title>A Study Adults With Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Inclusion criterion : Are ambulatory great equal 18 year age . Females childbearing potential must test negative pregnancy time enrollment base serum pregnancy test agree use highly reliable method birth control define result low failure rate ( &lt; 1 % per year ) study . Chronic psoriasis vulgaris least 6 month prior randomization . Moderate severe ( plaque ) psoriasis involve least 10 % body surface area ( BSA ) least 8 % BSA subject severe palmarplantar involvement randomization . Psoriasis Area Severity Index ( PASI ) total score least 12 screen . Exclusion criterion : Have clinically significant flare psoriasis 12 week prior randomization biologic agent/monoclonal antibody within long 5 half live 12 week prior dose , systemic treatment psoriasis phototherapy within 4 week prior dose , topical psoriasis treatment within 2 week prior dose . Have vaccination within 4 12 week ( depend type ) prior intend one within 4 week dose period . Are immunocompromised evidence active infection ( viral hepatitis and/or positive test tuberculosis human immunodeficiency virus [ HIV ] ) ; recent serious systemic infection ( mononucleosis herpes zoster ) . Have history current lymphoproliferative disease malignant disease ( except resolve cervical dysplasia ; 3 successfully treat basal squamous cell carcinoma skin ) , severe drug allergies/hypersensitivity . Have history serious cardiac disease within 12 week randomization ; serious unstable/uncontrolled illness include hepatic , renal , gastroenterologic , respiratory , cardiovascular , endocrinologic , neurologic , psychiatric , immunologic , hematologic disease condition , investigator 's opinion , could interfere analysis safety efficacy study . Have laboratory test value outside reference range population investigative site consider clinically significant and/or follow specific abnormality : Aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; 2 x upper limit normal ( ULN ; upper reference range central laboratory study ) Hemoglobin &lt; 100 g/L ( 10 g/dL ) White blood cell ( WBC ) &lt; 3.0 G/L ( 3,000/mm3 ) Neutrophils &lt; 1.5 G/L ( 1,500/mm3 ) Platelets &lt; 75 G/L ( 75,000/mm3 ) Serum creatinine &gt; 133 Âµmol/L ( 1.5 mg/dL ) Random glucose &gt; 11.1mmol/L ( 200 mg/dL ) . Have significant allergy humanize monoclonal antibody , clinically significant multiple severe drug allergy , intolerance topical corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>